Skip to main content
. 2022 Jan 11;11:818308. doi: 10.3389/fcimb.2021.818308

Table 2.

Univariate and multivariate Cox regression analysis of risk factors for 30-day mortality.

Variable Univariate analysis Multivariate analysis
HR a 95%CI for HR P value HR 95%CI for HR P value
Sex, male vs female 0.88 0.48-1.64 0.700
Age, y, ≥65 vs <65 2.01 1.03-3.92 0.040 2.03 0.83-4.98 0.121
Respiratory failure 3.24 1.87-5.63 <0.001 2.67 1.44-4.97 0.002
Heart failure 1.57 0.87-2.84 0.133
MODS 5.54 2.89-10.63 <0.001
SOFA, 1-point increments 1.28 1.17-1.40 <0.001 1.36 1.22-1.51 <0.001
WBC, × 109/L
4-10 vs <4 0.29 0.10-0.82 0.020
≥10 vs <4 0.64 0.25-1.65 0.358
Hemoglobin, g/L, <80 vs ≥80 1.96 1.13-3.41 0.017
Platelet, × 109/L, <100 vs ≥100 3.11 1.76-5.49 <0.001
CRP, mg/L, ≥150 vs <150 1.88 1.04-3.39 0.036
PCT, ng/mL, ≥5 vs <5 4.59 2.39-8.83 <0.001 3.54 1.82-6.86 <0.001
Albumin, g/L, <30 vs ≥30 4.1 2.30-7.31 <0.001
Tigecycline 1.69 0.98-2.94 0.061
Aminoglycosides 0.32 0.12-0.89 0.029
Fosfomycin 0.36 0.15-0.84 0.018
Number of anti-KP drugs
2 vs 1 0.76 0.41-1.41 0.389
3 vs 1 0.38 0.16-0.88 0.024
Appropriate treatments in 3 days 0.48 0.27-0.83 0.008 0.33 0.17-0.63 <0.001
a

HRs were calculated comparing with comorbidity and without comorbidity.

CI, confidence interval; HR, hazard ratio; MODA, multiple organ dysfunction syndrome; SOFA, Sequential Organ Failure Assessment; WBC, white blood count; CRP, c-reactive protein; PCT, procalcitonin; KP, Klebsiella pneumonia.